A 64-year-old Australian man was diagnosed with stage 3 breast cancer after his wife noticed bloodstains on his shirt, a case doctors say highlights that men can and do get the disease. Meanwhile, advances in precision medicine now allow breast cancer treatment to be tailored to each tumour’s biology and the patient’s overall health.
The FDA granted Rare Pediatric Disease designation to Atossa Therapeutics' (Z)-endoxifen for treating Duchenne Muscular Dystrophy. The designation may qualify the drug for a valuable Priority Review Voucher upon approval. Atossa reported a net loss of $34.8 million for 2025 as it advances clinical development.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07535905 |
Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients |
NOT_YET_RECRUITING | PHASE2 |
| NCT06979596 |
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) |
RECRUITING | PHASE2 |
| NCT06942039 |
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation |
RECRUITING | EARLY_PHASE1 |
| NCT06671912 |
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial |
SUSPENDED | PHASE3 |
| NCT06492616 |
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence |
RECRUITING | PHASE3 |
| NCT06440967 |
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06195306 |
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction |
RECRUITING | PHASE2 |
| NCT06184750 |
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial |
RECRUITING | PHASE2 |
| NCT06075953 |
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment |
RECRUITING | PHASE2 |
| NCT06001762 |
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer |
ACTIVE_NOT_RECRUITING | PHASE2 |
